SCHEMBL1665488

SCHEMBL1665488

CC(=O)c1cc(Cl)cs1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1771045 0.79
SCHEMBL788121 0.79
SCHEMBL545198 0.77
SCHEMBL826837 0.77 HPGD (0.38)
SCHEMBL10513732 0.77 GSK3B (0.44)
SCHEMBL19638255 0.77 CTPS1 (0.49)
SCHEMBL15177354 0.77 ALAD (0.72)
SCHEMBL7040071 0.76 CES2 (0.45)
SCHEMBL15988713 0.76 GSK3B (0.47)
Trimethylammonium SCHEMBL27777234 0.75 HPGD (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117486872-A Mechanical ball milling synthesis method of aminothiazole compound 浙江工业大学 2024-02-02 CN claimed
US-20250339402-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2025-11-06 US disclosed
EP-4511355-A2 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FundaMental Pharma GmbH (DE) 2025-02-26 EP disclosed
CN-119522208-A Effective methods for modulating NMDA receptor-mediated toxicity 智基药业有限公司 2025-02-25 CN disclosed
WO-2024223617-A1 EFFECTIVE MEANS TO MODULATE NMDA RECEPTOR-MEDIATED TOXICITY FUNDAMENTAL PHARMA GMBH (DE) 2024-10-31 WO disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
CN-117551093-B Preparation method of maleic acid atorvastatin (4-chloro-2-thienyl) -2-thiazole amine) as starting material 山东天锐医药科技有限公司 2024-06-18 CN disclosed
CN-117865951-A Method for preparing 4- (4-chloro-2-thienyl) -2-thiazolamine 苏州健雄职业技术学院 2024-04-12 CN disclosed
WO-2024059845-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 WO disclosed
WO-2007076423-A2 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 WO disclosed
WO-2007076423-A2 INHIBITORS OF Akt ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2007-07-05 WO disclosed
CN-1835948-A 2-acylaminothiazole derivative or its salt YAMANOUCHI PHARMA CO LTD (JP) 2006-09-20 CN disclosed
US-20060194844-A1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2006-08-31 US disclosed
EP-1647553-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2006-04-19 EP disclosed
US-20050153977-A1 2-Acylaminothiazole derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2005-07-14 US disclosed
EP-1466912-A1 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2004-10-13 EP disclosed
US-6613786-B2 Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction BRISTOL-MYERS SQUIBB COMPANY 2003-09-02 US disclosed
US-20030144333-A1 Thiophenyl triazol-3-one derivatives as smooth muscle relaxants HEWAWASAM PIYASENA (US) 2003-07-31 US disclosed
US-5030647-A Anti-inflammatory thienylbenzylamine compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1991-07-09 US disclosed